Anna Katharina Tietjen

Anna Katharina Tietjen

Auto-generated profile, based on publicly available information

Anna Katharina Tietjen

Complementary and Integrative Digital Health, Institute of Primary Care, University Hospital Zurich and University of Zurich, Zürich, Switzerland

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2019 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
TSTing Shi
Ting Shi
ADAngeline Denouel
Angeline Denouel
ATAnna K Tietjen
Anna K Tietjen
ICIain Campbell
Iain Campbell
EMEmily Moran
Emily Moran
HNHarish Nair
Harish Nair
Respiratory syncytial virus–associated acute respiratory infection (RSV-ARI) constitutes a substantial disease burden in older adults aged ≥65 years. We aimed to identify all studies worldwide investigating the disease burden of RSV-ARI in this population. We estimated the community incidence, hospitalization rate, and in-hospital case-fatality ratio (hCFR) of RSV-ARI in older adults, stratified by industrialized and developing regions, using data from a systematic review of studies published between January 1996 and April 2018 and 8 unpublished population-based studies. We applied these rate estimates to population estimates for 2015 to calculate the global and regional burdens in older adults with RSV-ARI in the community and in hospitals for that year. We estimated the number of in-hospital deaths due to RSV-ARI by combining hCFR data with hospital admission estimates from hospital-based studies. In 2015, there were about 1.5 million episodes (95% confidence interval [CI], .3 million–6.9 million) of RSV-ARI in older adults in industrialized countries (data for developing countries were missing), and of these, approximately 14.5% (214 000 episodes; 95% CI, 100 000–459 000) were admitted to hospitals. The global number of hospital admissions for RSV-ARI in older adults was estimated at 336 000 hospitalizations (uncertainty range [UR], 186 000–614 000). We further estimated about 14 000 in-hospital deaths (UR, 5000–50 000) related to RSV-ARI globally. The hospital admission rate and hCFR were higher for those aged ≥65 years than for those aged 50–64 years. The disease burden of RSV-ARI among older adults is substantial, with limited data from developing countries. Appropriate prevention and management strategies are needed to reduce this burden.

8 March 2019 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
TSTing Shi
Ting Shi
ADAngeline Denouel
Angeline Denouel
ATAnna K Tietjen
Anna K Tietjen
JLJen Wei Lee
Jen Wei Lee
AFAnn R Falsey
Ann R Falsey
HNHarish Nair
Harish Nair
Pneumonia constitutes a substantial disease burden among adults overall and those who are elderly. We aimed to identify all studies investigating the disease burden among older adults (age, ≥65 years) admitted to the hospital with pneumonia. We estimated the hospital admission rate and in-hospital case-fatality ratio (CFR) of pneumonia in older adults, stratified by age and economic status (industrialized vs developing), with data from a systematic review of studies published from 1996 through 2017 and from 8 unpublished population-based studies. We applied these rate estimates to population estimates for 2015 to calculate the global and regional burden in older adults who would have been admitted to the hospital with pneumonia that year. We estimated the number of in-hospital pneumonia deaths by combining in-hospital CFRs with hospital admission estimates from hospital-based studies. We identified 109 eligible studies; 73 used clinical pneumonia as the case definition, and 36 used radiologically confirmed pneumonia as the case definition. We estimated that, in 2015, 6.8 million episodes (uncertainty range [UR], 5.8–8.0 episodes) of clinical pneumonia resulted in hospital admissions of older adults worldwide. The hospital admission rate increased with advancing age and was higher in men. The total disease burden was likely underestimated when using the definition of radiologically confirmed pneumonia. Based on data from 52 hospital studies reporting data on pneumonia mortality, we estimated that about 1.1 million in-hospital deaths (UR, 0.9–1.4 in-hospital deaths) occurred among older adults. The burden of pneumonia requiring hospitalization among older adults is substantial. Appropriate prevention and management strategies should be developed to reduce its impact.

7 October 2021 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
ATAnna K. Tietjen
Anna K. Tietjen
NKNiklas Kroemer
Niklas Kroemer
DCDario Cattaneo
Dario Cattaneo
SBSara Baldelli
Sara Baldelli
SWSebastian Georg Wicha
Sebastian Georg Wicha
Aim: This study investigates the pharmacokinetic/pharmacodynamic (PK/PD) target attainment of linezolid in patients infected with multidrug‐resistant (MDR) tuberculosis (TB).Methods: A pharmacometric model was developed including 244 timed linezolid concentration samples from 39 patients employing NONMEM 7.4. The probability of target attainment (PTA, PK/PD target: unbound (f) area‐under‐the‐concentration‐time‐curve (AUC)/minimal inhibitory concentration (MIC) of 119) as well as a region‐specific cumulative fraction of response (CFR) were estimated for different dosing regimens.Results: A one‐compartment model with linear elimination with a clearance (CL) of 7.69 L/h (interindividual variability 34.1%), a volume of distribution (Vd) of 45.2 L and an absorption constant (KA) of 0.679 h−1 (interoccasion variability 143.7%) allometric scaled by weight best described the PK of linezolid. The PTA at an MIC of 0.5 mg/L was 55% or 97% if patients receiving 300 or 600 mg twice daily, respectively. CFRs varied greatly among populations and geographic regions. A desirable global CFR of ≥90% was achieved if linezolid was administered at a dose of 600 mg twice daily but not at a dose of 300 mg twice daily.Conclusion: This study showed that a dose of 300 mg twice daily of linezolid might not be sufficient to treat MDR‐TB patients from a PK/PD perspective. Thus, it might be recommendable to start with a higher dose of 600 mg twice daily to ensure PK/PD target attainment. Hereby, therapeutic drug monitoring and MIC determination should be performed to control PK/PD target attainment as linezolid shows high variability in its PK in the TB population.

2 March 2021 in Quality of Life Research
Verified
Journal Article
Open access
PDF file
ATAnna Katharina Tietjen
Anna Katharina Tietjen
RGRula Ghandour
Rula Ghandour
NMNahed Mikki
Nahed Mikki
LJLars Jerdén
Lars Jerdén
Jan W. ErikssonJan W. Eriksson
Jan W. Eriksson
AHAbdullatif Husseini
Abdullatif Husseini
Purpose: Type 2 diabetes mellitus (T2DM) is a considerable impact on physical health as well as on emotional and social wellbeing. This study aimed to investigate the quality of life and its associated factors among Palestinians with T2DM. Methods: A cross-sectional study including 517 patients (68% female) was conducted in eleven primary health care clinics located in Ramallah and al-Bireh governorate of the West Bank. To assess socio-demographic data, risk factors and diabetes control, interviews, physical examinations, anthropometric measurements, and blood and urine tests were performed. The validated Arabic version of the Audit of Diabetes-Dependent Quality of Life (ADDQoL) questionnaire was carried out on all patients to measure Quality of Life (QoL). A multivariable regression analysis was performed. Results: The average weighted impact (AWI) score was −3.38 (95% CI: −3.55 to −3.21, range: −9.00 to 0.12). This indicates that diabetes was perceived as having a considerable negative impact on the quality of life. The life domains ‘freedom to eat’, ‘physical activities’, and ‘work-life’ were the most negatively impacted. Males and individuals living with diabetes for a prolonged time were associated with a more significant negative impact on quality of life. Conclusion: The study showed that diabetes generally had a negative impact on QoL and identified the demand for diabetes management programs tailored to patient needs and different patient groups, as well as health policies that put patients in the center of diabetes care.

Verified
Journal Article
Open access
PDF file
MHMisa Hirose
Misa Hirose
AKAxel Künstner
Axel Künstner
PSPaul Schilf
Paul Schilf
ATAnna Katharina Tietjen
Anna Katharina Tietjen
OJOlaf Jöhren
Olaf Jöhren
SISaleh M. Ibrahim
Saleh M. Ibrahim
In this study, we provide experimental evidence that a maternally inherited polymorphism in the mitochondrial cytochrome b gene (mt-Cytb; m.15124A>G, Ile-Val) in mitochondrial complex III resulted in middle-aged obesity and higher susceptibility to diet-induced obesity, as well as age-related inflammatory disease, e.g., ulcerative dermatitis, in mice. As a consequence of the gene variation, we observed alterations in body composition, metabolism and mitochondrial functions, i.e., increased mitochondrial oxygen consumption rate and higher levels of reactive oxygen species, as well as in the commensal bacterial composition in the gut, with higher abundance of Proteobacteria in mice carrying the variant. These observations are in line with the previously described links of the mitochondrial complex III gene with obesity and metabolic diseases in humans. Given that these functional changes by the G variant at m.15124 in the mt-Cytb are already present in young mice that were kept under normal condition, it is plausible that the m.15124A>G variant is a disease susceptibility modifier to the diseases induced by additional stressors, i.e., dietary and/or aging stress, and that the variant results in the higher incidence of clinical diseases presentation in C57BL/6J-mt129S1/SvlmJ than C57BL/6J mice. Thus, mtDNA variants could be potential biomarkers to evaluate the healthspan.

14 May 2026 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Open access
JLJesus Lopez-Alcalde
Jesus Lopez-Alcalde
YYYuqian Yan
Yuqian Yan
CCClaudia Canella
Claudia Canella
JBJürgen Barth
Jürgen Barth
NSNina Steinemann
Nina Steinemann
CWClaudia M Witt
Claudia M Witt
A systematic visual presentation of clinical research on complementary therapies for people with multiple sclerosis (pwMS) can support clinical decisions and guide future research. To identify the interventions and outcomes evaluated in systematic reviews (SRs) and randomized clinical trials (RCTs) of complementary therapies for pwMS. Scoping review searching four databases for RCTs (any date) and SRs (since 2017). Results were presented in an evidence and gap map (EGM). The map displayed 63 complementary therapies, 30 outcomes of a core outcome set (COS) and 83 studies (46 SRs, 37 RCTs) published from 1977 to 2023. Most trials were small (26 (70.2%) had 100-200 participants) and conducted in Europe (n = 28; 75.6%). Natural products (n = 57 studies) and mind-body therapies (n = 12) were the most frequent groups of interventions. Cannabis (n = 24) and vitamins (n = 15) were the most frequent individual therapies. For 65.1% of the 63 listed interventions, there were no RCTs or SRs. Seventeen (56.7%) of the 30 core outcomes had fewer than five studies. Seven outcomes (23.3%) were not evaluated. The most frequent outcomes were ability to work/perform daily activities (n = 40 studies), safety (n = 37), health-related quality of life (n = 32), and fatigue (n = 31). This overview of RCTs and SRs of complementary therapies for pwMS indicates that the available research is scarce, with many interventions and outcomes unevaluated. Future RCTs should be adequately powered to assess outcomes relevant to pwMS. Efforts should be made to integrate research from non-Western studies to inform decisions.